EZH2 and prostate carcinoma: In support of this concept, a recent study found that inhibition of EZH2 activated a dsRNA–STING–IFN stress response that increased intratumoral trafficking of activated CD8+ T cells and sensitized prostate cancer cells to PD-1 checkpoint blockade (69).